Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032601 | 0.85 | NAAA (0.50) | NAAAFKBP1AMEN1POLBKMT2A | |
| SCHEMBL1664418 | 0.84 | NAAA (0.44) | NAAACHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL27176007 | 0.83 | FKBP1A (0.58) | NAAAFKBP1ALMNA | |
| SCHEMBL1664580 | 0.80 | L3MBTL1 (0.54) | ALDH1A1CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1663378 | 0.80 | NAAA (0.46) | NAAAFKBP1ACHRM2CHRM4CHRM5 | |
| SCHEMBL28457843 | 0.80 | FKBP1A (0.54) | NAAAFKBP1ACHRM2CHRM4CHRM5 | |
| SCHEMBL27205298 | 0.80 | FKBP1A (0.55) | NAAAFKBP1ALMNA | |
| SCHEMBL1664276 | 0.78 | NAAA (0.43) | NAAAFKBP1ACHRM2CHRM4CHRM5 | |
| SCHEMBL1663782 | 0.77 | FKBP1A (0.47) | NAAAFKBP1ALMNA | |
| SCHEMBL27567105 | 0.77 | FKBP1A (0.52) | NAAAFKBP1AALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011071674-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-06-16 | — | — | WO | disclosed |
| EP-2307476-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100113664-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2009152068-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | DDT, PCNA, AADAC | NAAA 509/4885FKBP1A 666/4885MEN1 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.